Abdoulaye Seck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Abdoulaye Seck has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Benoit Garin
Affiliation Experimental Bacteriology Unit, Institut Pasteur de Madagascar, Antananarivo, Madagascar
2 shared publicationsAbdou Diop
Medical Biology Laboratory, Institut Pasteur, Dakar
1 shared publication- Agathe de Lauzanne
Institut Pasteur du Cambodge, Epidemiology & Public Health Unit, Phnom Penh, Cambodia
1 shared publication Aminata Diaw Diouf
Laboratoire de Bactériologie-Virologie, Hôpital Le Dantec, Dakar, Senegal
1 shared publicationArmya Youssouf Abdou
Affiliations Université Paris-Saclay, UVSQ, Inserm, CESP, Anti-infective Evasion and Pharmacoepidemiology Team, Montigny-Le-Bretonneux, France, Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion (EMAE), Paris, France
1 shared publication- Babacar Ndiaye
Medical Biology Laboratory, Institut Pasteur, Dakar
1 shared publication
Latest Publications
- Open Access
- 22 April 2025
- Published by PAGEPress Publications in Microbiologia Medica
- Vol. 40 (1)
Optimizing urinary tract infection diagnosis: time and resource efficiency with the Sysmex UF-4000i
Background: Urinary Tract Infections (UTIs) are common bacterial infections, primarily caused by Gram-negative bacteria, such as Escherichia coli. They affect approximately 150 million individuals worldwide annually, leading to high healthcare costs and significant morbidity. The standard diagnostic method, urine culture, has a turnaround time of 48-72 hours, often necessitating empirical antibiotic treatment, which may contribute to antibiotic resistance. Rapid, accurate diagnostic tools are essential to improve clinical microbiology practices. Materials and Methods: this study evaluated the diagnostic accuracy of the Sysmex UF4000i flow cytometer for UTI detection, using traditional microscopy as the reference standard. Conducted over eight months at the Institut Pasteur, Dakar, it involved 2,322 urine samples analyzed via cytological examination and flow cytometry within two hours of collection. Bacterial cultures were performed on Chromagar Orientation media. Diagnostic performance was assessed using Receiver Operating Characteristic (ROC) curve analysis to establish a bacteriuria threshold for excluding UTIs. Results: among the 2,322 samples, bacteriuria was detected in 16.3%, with E. coli accounting for 60.7% of positive cultures. The Sysmex UF4000i showed high diagnostic accuracy, with an ROC Area Under the Curve (AUC) of 0.936. A cut-off of 9.85 bacteria/μL achieved a sensitivity of 99.1% and specificity of 53.2%, allowing for the exclusion of 44.9% of samples with a negative predictive value of 99.7%. Performance was consistent across subgroups, including children and women. Conclusions: the Sysmex UF4000i flow cytometer provides a rapid and reliable method for UTI screening, potentially reducing the need for manual urine cultures and minimizing antibiotic overuse while maintaining accuracy.
- 22 April 2025
- Published by PAGEPress Publications in Microbiologia Medica
- Vol. 40 (1)
Open AccessOptimizing urinary tract infection diagnosis: time and resource efficiency with the Sysmex UF-4000i
Background: Urinary Tract Infections (UTIs) are common bacterial infections, primarily caused by Gram-negative bacteria, such as Escherichia coli. They affect approximately 150 million individuals worldwide annually, leading to high healthcare costs and significant morbidity. The standard diagnostic method, urine culture, has a turnaround time of 48-72 hours, often necessitating empirical antibiotic treatment, which may contribute to antibiotic resistance. Rapid, accurate diagnostic tools are essential to improve clinical microbiology practices. Materials and Methods: this study evaluated the diagnostic accuracy of the Sysmex UF4000i flow cytometer for UTI detection, using traditional microscopy as the reference standard. Conducted over eight months at the Institut Pasteur, Dakar, it involved 2,322 urine samples analyzed via cytological examination and flow cytometry within two hours of collection. Bacterial cultures were performed on Chromagar Orientation media. Diagnostic performance was assessed using Receiver Operating Characteristic (ROC) curve analysis to establish a bacteriuria threshold for excluding UTIs. Results: among the 2,322 samples, bacteriuria was detected in 16.3%, with E. coli accounting for 60.7% of positive cultures. The Sysmex UF4000i showed high diagnostic accuracy, with an ROC Area Under the Curve (AUC) of 0.936. A cut-off of 9.85 bacteria/μL achieved a sensitivity of 99.1% and specificity of 53.2%, allowing for the exclusion of 44.9% of samples with a negative predictive value of 99.7%. Performance was consistent across subgroups, including children and women. Conclusions: the Sysmex UF4000i flow cytometer provides a rapid and reliable method for UTI screening, potentially reducing the need for manual urine cultures and minimizing antibiotic overuse while maintaining accuracy.
- Open Access
- 28 September 2021
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 18 (9) , e1003681
Severe bacterial neonatal infections in Madagascar, Senegal, and Cambodia: A multicentric community-based cohort study
Background: Severe bacterial infections (SBIs) are a leading cause of neonatal deaths in low- and middle-income countries (LMICs). However, most data came from hospitals, which do not include neonates who did not seek care or were treated outside the hospital. Studies from the community are scarce, and few among those available were conducted with high-quality microbiological techniques. The burden of SBI at the community level is therefore largely unknown. We aimed here to describe the incidence, etiology, risk factors, and antibiotic resistance profiles of community-acquired neonatal SBI in 3 LMICs. Methods and findings: The BIRDY study is a prospective multicentric community-based mother and child cohort study and was conducted in both urban and rural areas in Madagascar (2012 to 2018), Cambodia (2014 to 2018), and Senegal (2014 to 2018). All pregnant women within a geographically defined population were identified and enrolled. Their neonates were actively followed from birth to 28 days to document all episodes of SBI. A total of 3,858 pregnant women (2,273 (58.9%) in Madagascar, 814 (21.1%) in Cambodia, and 771 (20.0%) in Senegal) were enrolled in the study, and, of these, 31.2% were primigravidae. Women enrolled in the urban sites represented 39.6% (900/2,273), 45.5% (370/814), and 61.9% (477/771), and those enrolled in the rural sites represented 60.4% (1,373/2,273), 54.5% (444/814), and 38.1% (294/771) of the total in Madagascar, Cambodia, and Senegal, respectively. Among the 3,688 recruited newborns, 49.6% were male and 8.7% were low birth weight (LBW). The incidence of possible severe bacterial infection (pSBI; clinical diagnosis based on WHO guidelines of the Integrated Management of Childhood Illness) was 196.3 [95% confidence interval (CI) 176.5 to 218.2], 110.1 [88.3 to 137.3], and 78.3 [59.5 to 103] per 1,000 live births in Madagascar, Cambodia, and Senegal, respectively. The incidence of pSBI differed between urban and rural sites in all study countries. In Madagascar, we estimated an incidence of 161.0 pSBI per 1,000 live births [133.5 to 194] in the urban site and 219.0 [192.6 to 249.1] pSBI per 1,000 live births in the rural site (p = 0.008). In Cambodia, estimated incidences were 141.1 [105.4 to 189.0] and 85.3 [61.0 to 119.4] pSBI per 1,000 live births in urban and rural sites, respectively (p = 0.025), while in Senegal, we estimated 103.6 [76.0 to 141.2] pSBI and 41.5 [23.0 to 75.0] pSBI per 1,000 live births in urban and rural sites, respectively (p = 0.006). The incidences of culture-confirmed SBI were 15.2 [10.6 to 21.8], 6.5 [2.7 to 15.6], and 10.2 [4.8 to 21.3] per 1,000 live births in Madagascar, Cambodia, and Senegal, respectively, with no difference between urban and rural sites in each country. The great majority of early-onset infections occurred during the first 3 days of life (72.7%). The 3 main pathogens isolated were Klebsiella spp. (11/45, 24.4%), Escherichia coli (10/45, 22.2%), and Staphylococcus spp. (11/45, 24.4%). Among the 13 gram-positive isolates, 5 were resistant to gentamicin, and, among the 29 gram-negative isolates, 13 were resistant to gentamicin, with only 1 E. coli out of 10 sensitive to ampicillin. Almost one-third of the isolates were resistant to both first-line drugs recommended for the management of neonatal sepsis (ampicillin and gentamicin). Overall, 38 deaths occurred among neonates with SBI (possible and culture-confirmed SBI together). LBW and foul-smelling amniotic fluid at delivery were common risk factors for early pSBI in all 3 countries. A main limitation of the study was the lack of samples from a significant proportion of infants with pBSI including 35 neonatal deaths. Without these samples, bacterial infection and resistance profiles could not be confirmed. Conclusions: In this study, we observed a high incidence of neonatal SBI, particularly in the first 3 days of life, in the community of 3 LMICs. The current treatment for the management of neonatal infection is hindered by antimicrobial resistance. Our findings suggest that microbiological diagnosis of SBI remains a challenge in these settings and support more research on causes of neonatal death and the implementation of early interventions (e.g., follow-up of at-risk newborns during the first days of life) to decrease the burden of neonatal SBI and associated mortality and help achieve Sustainable Development Goal 3.
- 28 September 2021
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 18 (9) , e1003681
Open AccessSevere bacterial neonatal infections in Madagascar, Senegal, and Cambodia: A multicentric community-based cohort study
Background: Severe bacterial infections (SBIs) are a leading cause of neonatal deaths in low- and middle-income countries (LMICs). However, most data came from hospitals, which do not include neonates who did not seek care or were treated outside the hospital. Studies from the community are scarce, and few among those available were conducted with high-quality microbiological techniques. The burden of SBI at the community level is therefore largely unknown. We aimed here to describe the incidence, etiology, risk factors, and antibiotic resistance profiles of community-acquired neonatal SBI in 3 LMICs. Methods and findings: The BIRDY study is a prospective multicentric community-based mother and child cohort study and was conducted in both urban and rural areas in Madagascar (2012 to 2018), Cambodia (2014 to 2018), and Senegal (2014 to 2018). All pregnant women within a geographically defined population were identified and enrolled. Their neonates were actively followed from birth to 28 days to document all episodes of SBI. A total of 3,858 pregnant women (2,273 (58.9%) in Madagascar, 814 (21.1%) in Cambodia, and 771 (20.0%) in Senegal) were enrolled in the study, and, of these, 31.2% were primigravidae. Women enrolled in the urban sites represented 39.6% (900/2,273), 45.5% (370/814), and 61.9% (477/771), and those enrolled in the rural sites represented 60.4% (1,373/2,273), 54.5% (444/814), and 38.1% (294/771) of the total in Madagascar, Cambodia, and Senegal, respectively. Among the 3,688 recruited newborns, 49.6% were male and 8.7% were low birth weight (LBW). The incidence of possible severe bacterial infection (pSBI; clinical diagnosis based on WHO guidelines of the Integrated Management of Childhood Illness) was 196.3 [95% confidence interval (CI) 176.5 to 218.2], 110.1 [88.3 to 137.3], and 78.3 [59.5 to 103] per 1,000 live births in Madagascar, Cambodia, and Senegal, respectively. The incidence of pSBI differed between urban and rural sites in all study countries. In Madagascar, we estimated an incidence of 161.0 pSBI per 1,000 live births [133.5 to 194] in the urban site and 219.0 [192.6 to 249.1] pSBI per 1,000 live births in the rural site (p = 0.008). In Cambodia, estimated incidences were 141.1 [105.4 to 189.0] and 85.3 [61.0 to 119.4] pSBI per 1,000 live births in urban and rural sites, respectively (p = 0.025), while in Senegal, we estimated 103.6 [76.0 to 141.2] pSBI and 41.5 [23.0 to 75.0] pSBI per 1,000 live births in urban and rural sites, respectively (p = 0.006). The incidences of culture-confirmed SBI were 15.2 [10.6 to 21.8], 6.5 [2.7 to 15.6], and 10.2 [4.8 to 21.3] per 1,000 live births in Madagascar, Cambodia, and Senegal, respectively, with no difference between urban and rural sites in each country. The great majority of early-onset infections occurred during the first 3 days of life (72.7%). The 3 main pathogens isolated were Klebsiella spp. (11/45, 24.4%), Escherichia coli (10/45, 22.2%), and Staphylococcus spp. (11/45, 24.4%). Among the 13 gram-positive isolates, 5 were resistant to gentamicin, and, among the 29 gram-negative isolates, 13 were resistant to gentamicin, with only 1 E. coli out of 10 sensitive to ampicillin. Almost one-third of the isolates were resistant to both first-line drugs recommended for the management of neonatal sepsis (ampicillin and gentamicin). Overall, 38 deaths occurred among neonates with SBI (possible and culture-confirmed SBI together). LBW and foul-smelling amniotic fluid at delivery were common risk factors for early pSBI in all 3 countries. A main limitation of the study was the lack of samples from a significant proportion of infants with pBSI including 35 neonatal deaths. Without these samples, bacterial infection and resistance profiles could not be confirmed. Conclusions: In this study, we observed a high incidence of neonatal SBI, particularly in the first 3 days of life, in the community of 3 LMICs. The current treatment for the management of neonatal infection is hindered by antimicrobial resistance. Our findings suggest that microbiological diagnosis of SBI remains a challenge in these settings and support more research on causes of neonatal death and the implementation of early interventions (e.g., follow-up of at-risk newborns during the first days of life) to decrease the burden of neonatal SBI and associated mortality and help achieve Sustainable Development Goal 3.
- Open Access
- 1 February 2013
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 51 (2) , 578-584
HIV-1 Genetic Diversity and Drug Resistance among Senegalese Patients in the Public Health System
In this study, we investigated the prevalence of human immunodeficiency virus type 1 (HIV-1) drug resistance mutations and genetic variability among Senegalese patients undergoing highly active antiretroviral therapy (ART) in the public health system. We conducted a cross-sectional study of 72 patients with suspected therapeutic failure. HIV-1 genotyping was performed with Viroseq HIV-1 Genotyping System v2.0 or the procedure developed by the ANRS AC11 resistance study group, and a phylogenetic analysis was performed. The median follow-up visit was at 40 (range, 12 to 123) months, and the median viral load was 4.67 (range, 3.13 to 6.94) log10copies/ml. The first-line therapeutic regimen was nucleoside reverse transcriptase inhibitors (NRTIs) plus efavirenz (EFV) or NRTIs plus nevirapine (NVP) (54/72 patients; 75%), and the second-line therapy was NRTIs plus a protease inhibitor (PI/r) (18/72; 25%). Fifty-five patients (55/72; 76.39%) had at least one drug resistance mutation. The drug resistance rates were 72.22 and 88.89% for the first-line and second-line ARTs, respectively. In NRTI mutations, thymidine analog mutations (TAMs) were found in 50.79% and the M184V mutation was found in 34.92% of the samples. For non-NRTI resistance, we noted a predominance of the K103N mutation (46.27%). For PI/r, several cases of mutations were found with a predominance of M46I and L76V/F at 24% each. The phylogenetic analysis revealed CRF02_AG as the predominant circulating recombinant form (43/72; 59.72%). We found a high prevalence of resistance mutations and a high rate of TAMs among Senegalese patients in the public health system. These findings emphasize the need to improve virological monitoring in resource-limited settings.
- 1 February 2013
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 51 (2) , 578-584
Open AccessHIV-1 Genetic Diversity and Drug Resistance among Senegalese Patients in the Public Health System
In this study, we investigated the prevalence of human immunodeficiency virus type 1 (HIV-1) drug resistance mutations and genetic variability among Senegalese patients undergoing highly active antiretroviral therapy (ART) in the public health system. We conducted a cross-sectional study of 72 patients with suspected therapeutic failure. HIV-1 genotyping was performed with Viroseq HIV-1 Genotyping System v2.0 or the procedure developed by the ANRS AC11 resistance study group, and a phylogenetic analysis was performed. The median follow-up visit was at 40 (range, 12 to 123) months, and the median viral load was 4.67 (range, 3.13 to 6.94) log10copies/ml. The first-line therapeutic regimen was nucleoside reverse transcriptase inhibitors (NRTIs) plus efavirenz (EFV) or NRTIs plus nevirapine (NVP) (54/72 patients; 75%), and the second-line therapy was NRTIs plus a protease inhibitor (PI/r) (18/72; 25%). Fifty-five patients (55/72; 76.39%) had at least one drug resistance mutation. The drug resistance rates were 72.22 and 88.89% for the first-line and second-line ARTs, respectively. In NRTI mutations, thymidine analog mutations (TAMs) were found in 50.79% and the M184V mutation was found in 34.92% of the samples. For non-NRTI resistance, we noted a predominance of the K103N mutation (46.27%). For PI/r, several cases of mutations were found with a predominance of M46I and L76V/F at 24% each. The phylogenetic analysis revealed CRF02_AG as the predominant circulating recombinant form (43/72; 59.72%). We found a high prevalence of resistance mutations and a high rate of TAMs among Senegalese patients in the public health system. These findings emphasize the need to improve virological monitoring in resource-limited settings.
- 28 January 2013
- Published by Wiley in Helicobacter
- Vol. 18 (4) , 249-261
Impact of Human Migrations on Diversity of Helicobacter pylori in Cambodia and New Caledonia
Background Helicobacter pylori is a major gastric bacterial pathogen, presumed to have established itself in the human stomach approximately 100,000 years ago. Helicobacter pylori co-evolved with its host, and human migrations shaped the expansion and the diversity of strains around the world. Here, we investigated the population structure and the genomic diversity of H. pylori in New Caledonia and Cambodia, where humans of different origins are living. Methods Both multilocus sequence typing (MLST) and macro-array experiments were performed to assess polymorphism of housekeeping genes and to compare differences in gene contents among strains of H. pylori. Results The macro-array analysis based on variations of the flexible gene pools was consistent with the contribution of ancestral H. pylori populations to modern strains. Most of the CDS variably present encode proteins of unknown function, selfish DNA, and transposases. In New Caledonia—where humans are of several ethnic origins—strains belonged to four different genetic populations, reflecting the diversity of human populations. Melanesians and Polynesians were infected mainly by strains assigned to hspMaori, whereas Caucasians were infected by hspWAfrica, hpEurope, and hpNEAfrica strains. In contrast, strains from Khmer patients belonged to only two subpopulations: hspEAsia and hpEurope. In the two countries, both ancient and recent human migrations may have influenced the diversity of H. pylori. Conclusion Our present results are consistent with the possibility of admixture of strains in multiethnic communities. This increases the global polymorphism of H. pylori without evidence of functional change or impact on fitness and virulence.
- 28 January 2013
- Published by Wiley in Helicobacter
- Vol. 18 (4) , 249-261
Impact of Human Migrations on Diversity of Helicobacter pylori in Cambodia and New Caledonia
Background Helicobacter pylori is a major gastric bacterial pathogen, presumed to have established itself in the human stomach approximately 100,000 years ago. Helicobacter pylori co-evolved with its host, and human migrations shaped the expansion and the diversity of strains around the world. Here, we investigated the population structure and the genomic diversity of H. pylori in New Caledonia and Cambodia, where humans of different origins are living. Methods Both multilocus sequence typing (MLST) and macro-array experiments were performed to assess polymorphism of housekeeping genes and to compare differences in gene contents among strains of H. pylori. Results The macro-array analysis based on variations of the flexible gene pools was consistent with the contribution of ancestral H. pylori populations to modern strains. Most of the CDS variably present encode proteins of unknown function, selfish DNA, and transposases. In New Caledonia—where humans are of several ethnic origins—strains belonged to four different genetic populations, reflecting the diversity of human populations. Melanesians and Polynesians were infected mainly by strains assigned to hspMaori, whereas Caucasians were infected by hspWAfrica, hpEurope, and hpNEAfrica strains. In contrast, strains from Khmer patients belonged to only two subpopulations: hspEAsia and hpEurope. In the two countries, both ancient and recent human migrations may have influenced the diversity of H. pylori. Conclusion Our present results are consistent with the possibility of admixture of strains in multiethnic communities. This increases the global polymorphism of H. pylori without evidence of functional change or impact on fitness and virulence.